Prognostic Factors in IgA Nephropathy
The most critical prognostic factors for long-term renal outcomes in IgA nephropathy are proteinuria level (particularly time-averaged proteinuria), eGFR at presentation, blood pressure control, and specific histologic features on the Oxford MEST-C classification. 1, 2
Clinical Prognostic Factors
Proteinuria - The Dominant Predictor
Proteinuria is the single most important modifiable prognostic factor. The evidence consistently demonstrates:
- Proteinuria >1 g/day represents high risk for progression 3
- Proteinuria >0.5 g/day already indicates increased risk and warrants intervention 1, 4
- Time-averaged proteinuria is superior to single measurements for predicting outcomes 5
- Goal proteinuria should be <0.5 g/day, ideally <0.3 g/day to minimize lifetime risk of kidney failure 2
The 2025 KDIGO guideline lowered the treatment threshold from 1 g/day to 0.5 g/day based on accumulating evidence that even modest proteinuria levels confer significant long-term risk 2. Research confirms that patients with proteinuria 0.31-0.50 g/day already have nearly 4-fold increased risk of doubling serum creatinine 4.
eGFR at Presentation
Lower eGFR at diagnosis predicts worse outcomes, though it's unclear whether it independently predicts faster decline rates 3. Patients with eGFR <45 ml/min/1.73m² at biopsy have significantly higher risk (HR 2.35) 5.
Blood Pressure
Uncontrolled hypertension is an independent adverse prognostic factor 3. Target blood pressure should be:
The 2025 guideline further tightened this to <120/70 mmHg for all patients 7.
Histologic Prognostic Factors - Oxford MEST-C Classification
The Oxford Classification provides independent prognostic information beyond clinical parameters 1, 6. The validated histologic predictors are:
- M (Mesangial hypercellularity): >50% of glomeruli with hypercellularity
- E (Endocapillary hypercellularity): Presence predicts worse outcomes 3
- S (Segmental glomerulosclerosis): Strong predictor of progression 8
- T (Tubular atrophy/interstitial fibrosis): Most powerful histologic predictor; >25% involvement significantly worsens prognosis 3, 5
- C (Crescents): Added in 2016 revision; >50% crescents defines crescentic IgAN requiring aggressive therapy 1, 6
Important caveat: While histologic features provide independent prognostic information, clinical parameters (especially proteinuria and eGFR) often outweigh histology in multivariate models 8. The MEST-C score helps quantify risk but should not override clinical judgment.
Risk Stratification Tools
The International IgAN Prediction Tool should be used to quantify progression risk and guide shared decision-making 1. This validated tool incorporates:
- Clinical data at time of biopsy
- MEST-C histologic scores
- Cannot predict treatment response (only baseline risk) 1
Additional Prognostic Factors
Demographic and Laboratory
- Higher serum uric acid at biopsy predicts ESRD 9
- Smoking independently increases risk of renal death 10
- Male sex may confer worse prognosis in some cohorts
Treatment Response
Reduction of proteinuria to <1 g/day (ideally <0.5 g/day) is associated with favorable prognosis regardless of initial proteinuria level 3. This emphasizes that prognosis is not fixed but modifiable with appropriate therapy.
Long-Term Outcomes Context
Understanding baseline prognosis is critical:
IgAN is not a benign disease - approximately 50% of patients progress to ESRD within 30 years despite treatment 9. However, outcomes vary dramatically based on risk factors, with annual eGFR decline averaging -2.1 ml/min/1.73m²/year in treated cohorts 5.
Clinical Application Algorithm
- At diagnosis: Assess proteinuria, eGFR, blood pressure, and obtain MEST-C score from biopsy
- Calculate risk: Use International IgAN Prediction Tool
- Monitor: Serial proteinuria (time-averaged values), eGFR, and blood pressure
- Therapeutic targets:
- Proteinuria <0.5 g/day (ideally <0.3 g/day)
- Blood pressure <120/70 mmHg
- eGFR decline <1 ml/min/year
The goal is to return eGFR decline to physiological rates (<1 ml/min/year) for the patient's lifetime 2.